Skip to main content
UniHealth

Doctor search

Gwendolyn H Ho, MD

Hematology/Oncology · Stanford

NPI 1487970547

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
13
2 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

13 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ho’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

13 of 13 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend it
    Overall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital

Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Good Samaritan Hospital
Clostridium Difficile (C.Diff)Infections0.337BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.75 (0 to 1.67) · 1,340 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.84 (0.54 to 1.14)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths143.59 (98.7 to 188.49) · 98 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.7 · 45 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.1 · 100 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.7 · 270 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths11.3 · 573 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths15.6 · 820 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.5 · 482 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.3 · 3,711 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.12 (0 to 0.3) · 8,866 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.01 to 0.38) · 9,051 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths2.65 (0.74 to 4.56) · 1,929 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.8 (0.21 to 3.39) · 670 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.33 (0.88 to 3.78) · 1,836 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths6.73 (0 to 13.46) · 669 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths7.58 (3.96 to 11.19) · 654 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.59 (0.13 to 3.04) · 496 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.27 (0 to 0.87) · 7,373 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4.1 · 152 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections1.08No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.542No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.484No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.565No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits15.8 · 327 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits24.2 · 703 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits61.1 · 289 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits36.3 · 665 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits25.4 · 856 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits19 · 978 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits6.3 · 144 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits12.3 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits21.2 · 135 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.8 (10.1 to 18.6) · 129 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.2 (0.9 to 1.5) · 531 casesNo differentJan 2024 – Dec 2024

What patients said (704 patients answered, 24% of those asked)

Patient survey stars by topic at Good Samaritan Hospital
Cleanliness3
Nurse communication3
Doctor communication2
Communication about medicines2
Discharge information3
Overall hospital rating2
Quietness1
Recommend hospital3
Share of patients giving the best answer at Good Samaritan Hospital
Room was "always" clean66%
Nurses "always" communicated well75%
Doctors "always" communicated well71%
Staff "always" explained54%
Yes, staff "did" give patients this information83%
Yes, staff "did" give patients information about help after discharge81%
Doctors "always" explained things so they could understand66%
Doctors "always" listened carefully69%
Doctors "always" treated them with courtesy and respect78%
Patients who gave a rating of "9" or "10" (high)63%
Staff "always" explained new medications68%
Nurses "always" explained things so they could understand69%
Nurses "always" listened carefully73%
Nurses "always" treated them with courtesy and respect82%
"Always" quiet at night38%
"YES", patients would definitely recommend the hospital67%
Staff "always" explained possible side effects40%
Yes, staff "did" give patients information about possible symptoms86%
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$694,128

Medicare paid this office $694,128 for 220 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)88$32,210$162
Return visit (30+ min)106$21,706$111
Administration of chemotherapy into vein, 1 hour or less19$11,800$139
New patient visit (60+ min)25$4,553$182
Initial hospital care with moderate level of medical decision making at least 75 minutes29$4,444$153
See all 13 services
Every Original Medicare service billed
Long return visit (40+ min)88$32,210$162
Return visit (30+ min)106$21,706$111
Administration of chemotherapy into vein, 1 hour or less19$11,800$139
New patient visit (60+ min)25$4,553$182
Initial hospital care with moderate level of medical decision making at least 75 minutes29$4,444$153
New patient visit (45+ min)34$4,094$120
Short return visit (20+ min)40$3,444$77
Injection of additional new drug or substance into vein14$1,843$15
Administration of chemotherapy into vein, each additional hour11$1,473$27
Injection of drug or substance under skin or into muscle15$1,120$13
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle11$701$37
Infusion, normal saline solution , 1000 cc27$336None
Injection, dexamethasone sodium phosphate, 1 mg13$68None

Who their Medicare patients are

220 Original Medicare patients in 2024. Average age 77 · Women 49% · Also on Medicaid 19% · Health risk score 1.77. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.

Conditions among them: High blood pressure 69% · Cancer 37% · Coronary heart disease 29% · Heart failure 22% · Atrial fibrillation 22% · Chronic kidney disease 20% · Diabetes 16% · Depression 16% · Stroke 15% · COPD 11% · Dementia 8%.

The office billed $2,364,213, Medicare allowed $878,961 and paid $694,128; for 48,470 services of 73 kinds; $590,007 of it was for drugs given in the office and $104,121 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
202422048,470771.77$2,364,213$694,128
202328597,743761.67$3,696,483$1,059,159
202212526,644781.20$1,453,975$441,499
202112892661.65$126,301$33,129
202011687622.68$95,932$24,614
201913669652.01$112,143$27,175
2018151,195621.79$133,774$31,598
20171124652.06$4,865$1,224
20161415713.32$3,980$1,132
201484150683.05$37,114$10,791
20137275671.84$17,127$4,400

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 21 services

Original Medicare services billed in 2023
Long return visit (40+ min)101$53,052$163
Return visit (30+ min)107$36,095$114
Administration of chemotherapy into vein, 1 hour or less30$24,179$138
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)20$11,342$0
Initial hospital care with moderate level of medical decision making at least 75 minutes56$10,009$154
New patient visit (45+ min)67$9,883$148
New patient visit (60+ min)44$8,779$200
Administration of chemotherapy into vein, each additional hour26$7,611$28
Injection of additional new drug or substance into vein24$6,297$16
Short return visit (20+ min)59$5,820$76
Administration of additional new drug or substance into vein, 1 hour or less17$5,402$68
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes24$4,120$106
Biopsy and aspiration of bone marrow sample for diagnosis15$3,008$177
Injection of drug or substance into vein26$2,706$37
Injection of drug or substance under skin or into muscle24$2,122$14
Infusion into a vein for hydration, 31-60 minutes12$1,320$34
Infusion, normal saline solution , 1000 cc42$727None
Injection, palonosetron hcl, 25 mcg15$605None
Injection, dexamethasone sodium phosphate, 1 mg21$234None
Injection, ondansetron hydrochloride, per 1 mg13$61None
Injection, diphenhydramine hcl, up to 50 mg18$59None

2022: 12 services

Original Medicare services billed in 2022
Long return visit (40+ min)35$15,371$167
Administration of chemotherapy into vein, 1 hour or less17$12,981$141
Return visit (30+ min)47$11,937$119
New patient visit (45+ min)53$8,001$151
New patient visit (60+ min)27$5,291$196
Administration of chemotherapy into vein, each additional hour14$3,893$29
Injection of additional new drug or substance into vein16$3,033$16
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes16$2,977$90
Initial hospital care with moderate level of medical decision making at least 75 minutes15$2,790$174
Short return visit (20+ min)29$2,604$84
Injection, dexamethasone sodium phosphate, 1 mg13$88None
Injection, diphenhydramine hcl, up to 50 mg12$38None

2014: 4 services

Original Medicare services billed in 2014
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes15$2,599$84
Return visit (30+ min)42$2,476$54
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes11$930$58
Hospital discharge day management, 30 minutes or less11$705$59

2013: 1 service

Original Medicare services billed in 2013
Return visit (30+ min)61$3,786$59

Medicaid work

$11,203 in 2024

Medicaid paid $11,203 for 154 billed services this clinician did in 2024, up to 23 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)127$9,746
Return visit (30+ min)27$1,457
Medicaid work by year
2024154223$11,203
202374116$6,561
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)74$6,561

Drugs they prescribed that Part D paid

$875,766

Pharmacies billed $875,766 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 6% of their Part D prescriptions (25 of 448) in 2024. Above the middle of the specialty; the typical hematology-oncology clinician is at 5%.

346 generic and 102 brand-name prescriptions · $875,766 in drug cost · 15 antibiotic prescriptions to 14 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Brukinsa24$259,583$10,816
Orgovyx16$44,823$2,801
Venclexta11$42,869$3,897
Abiraterone Acetate38$17,240$454
Hydroxyurea32$1,008$31
See all 11 drugs
Every Part D drug this clinician prescribed
Brukinsa24$259,583$10,816
Orgovyx16$44,823$2,801
Venclexta11$42,869$3,897
Abiraterone Acetate38$17,240$454
Hydroxyurea32$1,008$31
Letrozole23$667$29
Ondansetron Odt26$377$15
Prednisone41$257$6
Dexamethasone13$246$19
Prochlorperazine Maleate15$208$14
Lorazepam13$87$7

Year by year

Part D prescribing by year
20244481006% (25)23%$875,766
20236481276% (36)None$971,190
20226271839% (56)None$1,072,120
20219261839% (79)23%$2,580,767
20208081717% (60)23%$2,144,482
20191,0371738% (85)27%$3,026,319
201876014110% (72)30%$2,079,801
20173797020% (74)21%$343,658
20164045117% (68)None$214,704
20154206113% (56)None$249,228
20143818413% (48)None$118,321
20136377916% (103)28%$41,149

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 17 drugs

Part D drugs prescribed in 2023
Ibrance13$230,081$17,699
Abiraterone Acetate47$193,117$4,109
Brukinsa12$182,657$15,221
Hydroxyurea48$2,550$53
Acyclovir16$741$46
Ondansetron Odt26$608$23
Letrozole27$592$22
Prednisone83$521$6
Dexamethasone26$484$19
Hydrocodone-Acetaminophen16$467$29
Prochlorperazine Maleate24$278$12
Mirtazapine11$239$22
Ondansetron21$225$11
Levofloxacin16$203$13
Furosemide19$113$6
Lorazepam15$92$6
Trazodone12$68$6

2022: 15 drugs

Part D drugs prescribed in 2022
Ibrance24$330,168$13,757
Abiraterone Acetate20$99,410$4,970
Eliquis14$7,926$566
Hydroxyurea58$3,585$62
Letrozole60$1,325$22
Anastrozole39$977$25
Dexamethasone14$394$28
Ondansetron21$349$17
Ondansetron Odt12$346$29
Prochlorperazine Maleate28$296$11
Prednisone33$237$7
Alendronate16$166$10
Tramadol12$88$7
Furosemide13$82$6
Lorazepam18$61$3

2021: 23 drugs

Part D drugs prescribed in 2021
Revlimid40$644,444$16,111
Ibrance42$528,702$12,588
Imbruvica30$437,050$14,568
Pomalyst11$227,856$20,714
Venclexta11$94,824$8,620
Zarxio14$13,039$931
Hydroxyurea67$4,216$63
Imatinib Mesylate12$3,146$262
Letrozole113$2,787$25
Dexamethasone55$1,556$28
Anastrozole60$1,467$24
Exemestane16$1,334$83
Acyclovir36$1,057$29
Ondansetron44$507$12
Prednisone42$414$10
Gabapentin17$349$21
Hydrocodone-Acetaminophen19$308$16
Hydromorphone11$295$27
Prochlorperazine Maleate11$248$23
Tramadol23$189$8
Trazodone12$168$14
Alendronate15$156$10
Lorazepam16$120$8

2020: 18 drugs

Part D drugs prescribed in 2020
Revlimid45$692,723$15,394
Ibrance39$501,205$12,851
Imbruvica21$281,255$13,393
Exemestane15$4,033$269
Imatinib Mesylate17$3,339$196
Hydroxyurea53$2,636$50
Dexamethasone61$2,412$40
Letrozole97$2,391$25
Anastrozole61$1,491$24
Hydrocodone-Acetaminophen23$591$26
Acyclovir13$589$45
Prochlorperazine Maleate14$374$27
Ondansetron31$313$10
Gabapentin12$257$21
Diphenoxylate-Atropine11$248$23
Furosemide17$133$8
Alendronate12$125$10
Lorazepam16$123$8

2019: 24 drugs

Part D drugs prescribed in 2019
Ibrance103$1,327,962$12,893
Revlimid61$922,245$15,119
Jakafi15$307,972$20,531
Imbruvica18$216,334$12,019
Zarxio26$40,485$1,557
Imatinib Mesylate21$3,855$184
Exemestane13$3,329$256
Letrozole112$2,729$24
Dexamethasone82$2,598$32
Entecavir19$2,392$126
Hydroxyurea47$2,143$46
Anastrozole66$1,593$24
Tamoxifen Citrate15$861$57
Hydrocodone-Acetaminophen34$748$22
Hydromorphone14$627$45
Venlafaxine13$410$32
Prednisone46$402$9
Ondansetron42$401$10
Prochlorperazine Maleate24$390$16
Gabapentin17$320$19
Lorazepam30$216$7
Furosemide13$135$10
Tramadol11$131$12
Allopurinol11$122$11

2018: 17 drugs

Part D drugs prescribed in 2018
Ibrance90$1,108,193$12,313
Revlimid30$411,132$13,704
Imbruvica25$292,725$11,709
Zarxio27$60,856$2,254
Letrozole79$1,903$24
Dexamethasone50$1,331$27
Anastrozole31$812$26
Hydrocodone-Acetaminophen37$734$20
Hydroxyurea12$536$45
Ondansetron25$394$16
Prednisone37$315$9
Prochlorperazine Maleate25$262$10
Lorazepam30$237$8
Famotidine11$173$16
Furosemide21$138$7
Trazodone12$107$9
Allopurinol11$87$8

2017: 9 drugs

Part D drugs prescribed in 2017
Imbruvica15$151,275$10,085
Enoxaparin13$9,167$705
Hydrocodone-Acetaminophen40$745$19
Oxycodone15$509$34
Letrozole19$390$21
Ondansetron14$285$20
Lorazepam34$219$6
Acyclovir12$116$10
Sulfamethoxazole-Trimethoprim12$32$3

2016: 11 drugs

Part D drugs prescribed in 2016
Neupogen13$33,904$2,608
Hydrocodone-Acetaminophen37$1,530$41
Polyethylene Glycol 335011$307$28
Oxycodone19$286$15
Ondansetron22$224$10
Pantoprazole12$127$11
Lorazepam29$122$4
Prochlorperazine Maleate16$94$6
Amlodipine Besylate20$93$5
Famotidine14$36$3
Furosemide11$25$2

2015: 9 drugs

Part D drugs prescribed in 2015
Baraclude11$11,669$1,061
Hydrocodone-Acetaminophen26$1,242$48
Ondansetron34$541$16
Oxycodone14$261$19
Pantoprazole21$175$8
Lorazepam31$143$5
Prednisone16$130$8
Prochlorperazine Maleate15$85$6
Potassium Chloride11$77$7

2014: 9 drugs

Part D drugs prescribed in 2014
Morphine Sulfate Er11$2,760$251
Pravastatin18$434$24
Hydrocodone-Acetaminophen17$380$22
Ondansetron19$353$19
Gabapentin14$244$17
Levothyroxine13$202$16
Atorvastatin11$159$14
Lorazepam20$85$4
Lisinopril11$45$4

2013: 18 drugs

Part D drugs prescribed in 2013
Lantus22$4,261$194
Novolog12$2,917$243
Morphine Sulfate Er26$1,661$64
Hydrocodone-Acetaminophen59$1,273$22
Gabapentin27$1,253$46
Divalproex13$1,220$94
Xopenex Hfa15$751$50
Omeprazole22$510$23
Montelukast11$505$46
Metoprolol12$428$36
Polyethylene Glycol 335012$398$33
Synthroid11$273$25
Amlodipine Besylate25$212$8
Lisinopril26$173$7
Levothyroxine14$166$12
Hydrochlorothiazide13$108$8
Metformin13$99$8
Metoprolol16$97$6

Money from drug and device companies

$36 in 2025

Industry payments by year
202522None$36
202322None$40
202212None$29

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Daiichi SankyoEnhertu$18
1 payment
  • Meals for Enhertu · 2025-10-16 · $18
AstraZeneca Pharmaceuticals LPEnhertu$17
1 payment
  • Meals for Enhertu · 2025-10-17 · $17
See all 2 published payments
Every published payment
AstraZeneca Pharmaceuticals LPMeals · 2025-10-17Enhertu$17
Daiichi SankyoMeals · 2025-10-16Enhertu$18
See earlier years (2023, 2022)

2023: $40

Payments by company in 2023
PfizerIbrance$25
1 payment
  • Education for Ibrance · 2023-09-22 · $25
EMD SeronoTepmetko$15
1 payment
  • Meals for Tepmetko · 2023-10-09 · $15

2022: $29

Payments by company in 2022
CelgeneReblozyl$29
2 payments
  • Meals for Reblozyl · 2022-12-15 · $16
  • Meals for Reblozyl · 2022-09-01 · $13

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Merck Sharp & Dohme LLC · A Phase 2 Study To Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase Mk-3475a Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types Mk-3475a-F11 · 2024Their institution$188,249
Merck Sharp & Dohme LLC · A Phase 2 Study To Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase Mk-3475a Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types Mk-3475a-F11 · 2023Their institution$149

Professional record

NPI
1487970547
Licence
CA A1189808
Trained
University of California, San Francisco School of Medicine, 2010
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X); Medical oncology (207RX0202X)
Mailing address
2589 Samaritan Dr, San Jose, CA, 95124
NPI first listed
2010-04-14
NPI last updated
2025-01-23
NPI record certified
2025-01-23

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 4501 X St Ste 3016, Sacramento, CA, 95817

This office lists an electronic records connection.